Skd Pharma Products Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 24-10-2024
- Paid Up Capital ₹ 7.50 M
as on 24-10-2024
- Company Age 9 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.21 Cr
as on 24-10-2024
- Revenue 15.51%
(FY 2023)
- Profit 32.22%
(FY 2023)
- Ebitda 5.27%
(FY 2023)
- Net Worth 73.86%
(FY 2023)
- Total Assets 3.09%
(FY 2023)
About Skd Pharma Products
The Company is engaged in the Packaging Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 7.50 M.
The company currently has active open charges totaling ₹2.21 Cr.
Vijayalakshmi Konduru and Konduru Raju serve as directors at the Company.
- CIN/LLPIN
U25203TG2015PTC100184
- Company No.
100184
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Aug 2015
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Skd Pharma Products Private Limited offer?
Skd Pharma Products Private Limited offers a wide range of products and services, including Packaging Caps & Seals, Packing Seals, Vials and Ampoules, Flip Off Seal.
Who are the key members and board of directors at Skd Pharma Products?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vijayalakshmi Konduru  | Director | 11-Aug-2015 | Current |
| Konduru Raju | Director | 12-May-2020 | Current |
Financial Performance of Skd Pharma Products.
Skd Pharma Products Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 15.51% increase. The company also saw a substantial improvement in profitability, with a 32.22% increase in profit. The company's net worth Soared by an impressive increase of 73.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Skd Pharma Products?
In 2023, Skd Pharma Products had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 23 Nov 2023 | ₹1.40 M | Open |
Canara Bank Creation Date: 30 Aug 2023 | ₹1.60 Cr | Open |
Canara Bank Creation Date: 09 Dec 2020 | ₹3.50 M | Open |
How Many Employees Work at Skd Pharma Products?
Skd Pharma Products has a workforce of 13 employees as of Mar 23, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Skd Pharma Products, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Skd Pharma Products's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
